focus -WSS

focus

author：comprehensive 2025-08-23 03:45:04 - browse：9

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Goldman Sachs launches $650M fund for life science investments

focus

WSS

Chronically ill young patients struggle to find fertility info

Morgan Health, with ambitious aims, wants you to know it’s still here

GSK Flovent asthma inhalers replaced by authorized generics

UCB departs biotech trade group BIO

Questions loom on AstraZeneca cancer drug as safety concerns ebb

CZI to create biohub to build anti

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Drug repurposing or repositioning? The language matters

Study on Amgen’s bispecific immunotherapy produces positive data

At least 13 dead in Texas as scorching temps continue

3 trends to watch in health tech's hiring outlook for 2024

BioMarin wins approval for gene therapy to treat hemophilia A

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Alkermes shareholders re

J&J lung cancer data amount to new salvo against AstraZeneca

Psychedelics group wrestles with new pharma identity

STAT Readout: Friday, Oct. 20 biotech updates

explore

3 medical device trends to watch in 2024

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

White House finalizes ITC's import ban of latest Apple Watches

ADCs take center stage as promising cancer treatments

STAT Summit: Meghan O’Rourke on making chronic illness visible

J&J to buy cancer drug developer Ambrx Biopharma

focus

Wikipedia

focus

focus